CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 142 enrolled
Drug / intervention
Abemaciclib +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02079636
NCT02079636Phase 1Completed
CompareCT.gov

A Phase 1b Study of LY2835219 in Combination With Multiple Single Agent Options for Patients With Stage IV NSCLC

Eli Lilly and Company·interventional·Posted Mar 6, 2014·Updated Sep 11, 2020

In Brief

A Phase 1 clinical trial evaluating Abemaciclib, Pemetrexed, and 4 other interventions for Carcinoma, Non-small Cell Lung. Completed, enrolled 142 participants across 11 sites in 2 countries.

Detailed Summary

The main purpose of this study is to evaluate the safety and tolerability of abemaciclib in combination with another anti-cancer drug in participants with NSCLC that is advanced or has spread to other parts of the body (stage IV). The study will also investigate how the body processes the combination treatment and how the study drug affects the body. The study will also collect disease-related symptoms and participant-reported pain related to NSCLC.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non-small Cell Lung
CountriesSpain, United States
CollaboratorsMerck Sharp & Dohme LLC

Timeline

Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 6, 2014
Enrollment StartMar 28, 2014
Primary CompletionMay 2, 2018
Study CompletionAug 29, 2019
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 12.3 years ago

Interventions

Abemaciclibdrug

Administered orally

Pemetrexeddrug

Administered IV

Gemcitabinedrug

Administered IV

Ramucirumabdrug

Administered IV

LY3023414drug

Administered orally

Pembrolizumabdrug

Administered IV